Hueber Arno, Roters Sigrid, Jordan Jens F, Konen Walter
BMC Ophthalmol. 2013 Jul 18;13:35. doi: 10.1186/1471-2415-13-35.
To evaluate the success rate and adverse effects of Gold Micro Shunt Plus (GMS+) implantation into the supraciliary space.
This retrospective study included 31 eyes of 31 patients diagnosed with severe glaucoma and uncontrolled intraocular pressure (IOP) with implantation of a GMS+ by means of a full-thickness scleral flap. The main outcome measures were surgical failure or success, based on the intraocular pressure and adverse effects. Clinical examination data are reported up to 4 years postoperatively.
Thirty eyes (97%) met one of our criteria for failure. Within a mean of 7.3 ± 7.7 months another surgery was performed because of elevated IOP in 24 of 31 eyes (77%) and because of adverse effects in 2 (6%). The remaining 4 eyes, that met one of our criteria for failure, had an IOP reduction of less than 20% with comparable medication. Six GMS+'s were explanted; because of IOP elevation, 2; rubeosis iridis, 2; and low grade inflammation, 2.
GMS+ implantation is not an effective method to control IOP in patients with glaucoma, when using our surgical technique. The reason for the found signs of chronic low grade inflammation or rubeosis iridis in 4 eyes (13%) remains unknown and has to be further investigated.
评估Gold Micro Shunt Plus（GMS+）植入睫状体上腔的成功率和不良反应。
这项回顾性研究纳入了31例诊断为重度青光眼且眼压控制不佳的患者的31只眼，通过全层巩膜瓣植入GMS+。主要观察指标为基于眼压和不良反应的手术失败或成功情况。报告术后4年的临床检查数据。
30只眼（97%）符合我们的失败标准之一。在平均7.3±7.7个月内，31只眼中有24只眼（77%）因眼压升高、2只眼（6%）因不良反应进行了再次手术。其余4只符合我们失败标准之一的眼，在使用类似药物的情况下眼压降低不到20%。取出了6个GMS+；2个因眼压升高，2个因虹膜红变，2个因低度炎症。
采用我们的手术技术时，GMS+植入并非控制青光眼患者眼压的有效方法。4只眼（13%）出现慢性低度炎症或虹膜红变迹象的原因尚不清楚，有待进一步研究。
